Search

Your search keyword '"Luijk, B."' showing total 121 results
Start Over Author "Luijk, B."
121 results on '"Luijk, B."'

2. WS01.03 Effects of elexacaftor/tezacaftor/ivacaftor in lung transplant recipients with cystic fibrosis: the Dutch national KOALA study

Author

van Gemert, J.P., primary, Luijk, B., additional, Hellemons, M.E., additional, Visser, K.A., additional, Hansen, C., additional, Meer, R. van der, additional, Gan, T., additional, Vaart, H. van der, additional, Akkerman, O.W., additional, Steenhuis, W.N., additional, Verkleij, M., additional, Heijerman, H.G.M., additional, and Verschuuren, E.A.M., additional

Published
2024
Full Text
View/download PDF

5. The relationship of fat and muscle measurements with emphysema and bronchial wall thickening in smokers

Author

Cancer, Researchgr. Systems Radiology, Arts-assistenten Radiologie, Arts-Assistenten Onderwijs Radiologie, Beeldverwerking ISI, Regenerative Medicine and Stem Cells, Infection & Immunity, Circulatory Health, Longziekten, MS Radiologie, Bunk, Stijn, Ipema, Jetty, Sidorenkov, Grigory, Bennink, E, Vliegenthart, Rozemarijn, de Jong, Pim, Pompe, Esther, Charbonnier, Jean-Paul, Luijk, B., Aerts, Joachim, Groen, Harry, Mohamed Hoesein, Firdaus, Cancer, Researchgr. Systems Radiology, Arts-assistenten Radiologie, Arts-Assistenten Onderwijs Radiologie, Beeldverwerking ISI, Regenerative Medicine and Stem Cells, Infection & Immunity, Circulatory Health, Longziekten, MS Radiologie, Bunk, Stijn, Ipema, Jetty, Sidorenkov, Grigory, Bennink, E, Vliegenthart, Rozemarijn, de Jong, Pim, Pompe, Esther, Charbonnier, Jean-Paul, Luijk, B., Aerts, Joachim, Groen, Harry, and Mohamed Hoesein, Firdaus

Published
2024

8. Maintenance and reliever therapy with budesonide/formoterol versus fixed dose fluticasone/salmeterol in patients with COPD

Author

Muiser, S, primary, Imkamp, K, additional, Seigers, D, additional, Halbersma, N, additional, Vonk, J, additional, Luijk, B, additional, Braunstahl, G, additional, Van Den Berg, J W, additional, Kroesen, B, additional, Kocks, J, additional, Heijink, I, additional, Reddel, H, additional, Kerstjens, H, additional, and Van Den Berge, M, additional

Published
2022
Full Text
View/download PDF

12. Prediction of Survival after Chronic Lung Allograft Dysfunction in Lung Transplant Recipients by Blood Profiling Using a Predefined 52 Gene Signature

Author

Longziekten, Infection & Immunity, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, CTI Otten, CTI Budding, CDL Patiëntenzorg MI, Luijk, B., Krebber, M., Li, Q., Kardol-Hoefnagel, T., Budding, K., van Kessel, D. A., Grutters, J. C., Otten, H. G., Kaminski, N., Maya, J. D. Herazo, Longziekten, Infection & Immunity, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, CTI Otten, CTI Budding, CDL Patiëntenzorg MI, Luijk, B., Krebber, M., Li, Q., Kardol-Hoefnagel, T., Budding, K., van Kessel, D. A., Grutters, J. C., Otten, H. G., Kaminski, N., and Maya, J. D. Herazo

Published
2021

15. Impact of donor lung quality on post-transplant recipient outcome in the Lung Allocation Score era in Eurotransplant – a historical prospective study

Author

Smits, J.M.A. (J. M A), Gottlieb, J. (Jens), Verschuuren, E.A., Evrard, P. (Patrick), Hoek, R.A.S. (Rogier), Knoop, C. (Christiane), Lang, G. (György), Kwakkel-van Erp, H. (Hanneke), Vos, R. (Robin), Verleden, G. (Geert), Rondelet, B. (Benoit), Hoefer, D. (Daniel), Langer, F. (Frank), Schramm, R. (Rene), Hoetzenecker, K. (Konrad), van Kessel, D.A. (Diana A.), Luijk, B. (Bart), Seghers, L., Deuse, T. (Tobias), Buhl, R. (Roland), Witt, C. (Christian), Strelniece, A. (Agita), Green, D. (Dave), de Vries, E. (Erwin), Laufer, G. (Guenter), Van Raemdonck, D. (Dirk), Smits, J.M.A. (J. M A), Gottlieb, J. (Jens), Verschuuren, E.A., Evrard, P. (Patrick), Hoek, R.A.S. (Rogier), Knoop, C. (Christiane), Lang, G. (György), Kwakkel-van Erp, H. (Hanneke), Vos, R. (Robin), Verleden, G. (Geert), Rondelet, B. (Benoit), Hoefer, D. (Daniel), Langer, F. (Frank), Schramm, R. (Rene), Hoetzenecker, K. (Konrad), van Kessel, D.A. (Diana A.), Luijk, B. (Bart), Seghers, L., Deuse, T. (Tobias), Buhl, R. (Roland), Witt, C. (Christian), Strelniece, A. (Agita), Green, D. (Dave), de Vries, E. (Erwin), Laufer, G. (Guenter), and Van Raemdonck, D. (Dirk)

Abstract

The aim of this study was to investigate whether there is an impact of donation rates on the quality of lungs used for transplantation and whether donor lung quality affects post-transplant outcome in the current Lung Allocation Score era. All consecutive adult LTx performed in Eurotransplant (ET) between January 2012 and December 2016 were included (N = 3053). Donors used for LTx in countries with high donation rate were younger (42% vs. 33% ≤45 years, P < 0.0001), were less often smokers (35% vs. 46%, P < 0.0001), had more often clear chest X-rays (82% vs. 72%, P < 0.0001), had better donor oxygenation ratios (20% vs. 26% with PaO2/FiO2 ≤ 300 mmHg, P < 0.0001), and had better lung donor score values (LDS; 28% vs. 17% with LDS = 6, P < 0.0001) compared with donors used for LTx in countries with low donation rate. Survival rates for the groups LDS = 6 and ≥7 at 5 years were 69.7% and 60.9% (P = 0.007). Lung donor quality significantly impacts on long-term patient survival. Countries with a low donation rate are more oriented to using donor lungs with a lesser quality compared to countries with a high donation rate. Instead of further stretching donor eligibility criteria, the full potential of the donor pool should be realized.

Published
2020
Full Text
View/download PDF

16. Exceptional LAS Requests in Eurotransplant: Analysis of an 8-year Effort to Improve Lung Allocation for Precarious Patients

Author

Longziekten, Infection & Immunity, Vos, R., Smits, J. M., Hoek, R., Green, D., Evrard, P., Knoop, C., Verleden, G. M., Rondelet, B., Kwakkel-vanErp, J. M., Seghers, L., van Kessel, D. A., Luijk, B., Verschuuren, E. A., Lang, G., Hoetzenecker, K., Laufer, G., Hoefer, D., Langer, F., Schramm, R., Deuse, T., Buhl, R., Witt, C., Gottlieb, J., Longziekten, Infection & Immunity, Vos, R., Smits, J. M., Hoek, R., Green, D., Evrard, P., Knoop, C., Verleden, G. M., Rondelet, B., Kwakkel-vanErp, J. M., Seghers, L., van Kessel, D. A., Luijk, B., Verschuuren, E. A., Lang, G., Hoetzenecker, K., Laufer, G., Hoefer, D., Langer, F., Schramm, R., Deuse, T., Buhl, R., Witt, C., and Gottlieb, J.

Published
2020

19. Exceptional LAS Requests in Eurotransplant: Analysis of an 8-year Effort to Improve Lung Allocation for Precarious Patients

Author

Vos, R., primary, Smits, J.M., additional, Hoek, R., additional, Green, D., additional, Evrard, P., additional, Knoop, C., additional, Verleden, G.M., additional, Rondelet, B., additional, Kwakkel-vanErp, J.M., additional, Seghers, L., additional, van Kessel, D.A., additional, Luijk, B., additional, Verschuuren, E.A., additional, Lang, G., additional, Hoetzenecker, K., additional, Laufer, G., additional, Hoefer, D., additional, Langer, F., additional, Schramm, R., additional, Deuse, T., additional, Buhl, R., additional, Witt, C., additional, and Gottlieb, J., additional

Published
2020
Full Text
View/download PDF

27. A Multicenter Study on Long-Term Outcomes After Lung Transplantation Comparing Donation After Circulatory Death and Donation After Brain Death

Author

van Suylen, V. (V.), Luijk, B. (Bart), Hoek, R.A.S. (Rogier), van de Graaf, E.A. (Ed A.), Verschuuren, E.A., Van De Wauwer, C. (C.), Bekkers, J.A. (Jos), Meijer, R.C.A. (Ronald C.A.), Bij, W. (Wim) van der, Erasmus, M.E. (M. E.), van Suylen, V. (V.), Luijk, B. (Bart), Hoek, R.A.S. (Rogier), van de Graaf, E.A. (Ed A.), Verschuuren, E.A., Van De Wauwer, C. (C.), Bekkers, J.A. (Jos), Meijer, R.C.A. (Ronald C.A.), Bij, W. (Wim) van der, and Erasmus, M.E. (M. E.)

Abstract

The implementation of donation after circulatory death category 3 (DCD3) was one of the attempts to reduce the gap between supply and demand of donor lungs. In the Netherlands, the total number of potential lung donors was greatly increased by the availability of DCD3 lungs in addition to the initial standard use of donation after brain death (DBD) lungs. From the three lung transplant centers in the Netherlands, 130 DCD3 recipients were one-to-one nearest neighbor propensity score matched with 130 DBD recipients. The primary end points were primary graft dysfunction (PGD), posttransplant lung function, freedom from chronic lung allograft dysfunction (CLAD), and overall survival. PGD did not differ between the groups. Posttransplant lung function was comparable after bilateral lung transplantation, but seemed worse after DCD3 single lung transplantation. The incidence of CLAD (p = 0.17) nor the freedom from CLAD (p = 0.36) nor the overall survival (p = 0.40) were significantly different between both groups. The presented multicenter results are derived from a national context where one third of the lung transplantations are performed with DCD3 lungs. We conclude that the long-term outcome after lung transplantation with DCD3 donors is similar to that of DBD donors and that DCD3 donation can substantially enlarge the donor pool.

Published
2017
Full Text
View/download PDF

28. A Multicenter Study on Long-Term Outcomes After Lung Transplantation Comparing Donation After Circulatory Death and Donation After Brain Death

Author

Longziekten, Infection & Immunity, Orthopaedie Opleiding, CTC, Circulatory Health, van Suylen, R.J., Luijk, B, Hoek, R.A.S., van de Graaf, E A, Verschuuren, Erik A, Van De Wauwer, C, Bekkers, J A, Meijer, R C A, van der Bij, Wim, Erasmus, M. E., Longziekten, Infection & Immunity, Orthopaedie Opleiding, CTC, Circulatory Health, van Suylen, R.J., Luijk, B, Hoek, R.A.S., van de Graaf, E A, Verschuuren, Erik A, Van De Wauwer, C, Bekkers, J A, Meijer, R C A, van der Bij, Wim, and Erasmus, M. E.

Published
2017

32. Effective Prolonged Therapy with Voriconazole in a Lung Transplant Recipient with Spondylodiscitis Induced by Scedosporium apiospermum

Author

Luijk, B., Ekkelenkamp, M. B., De Jong, P. A., Kwakkel-van Erp, J. M., Grutters, J. C., van Kessel, D. A., and van de Graaf, E. A.

Subjects
Article Subject
Abstract

Scedosporium/Pseudallescheria species are frequently seen in cystic fibrosis patients. However, disseminated forms after lung transplantation in these patients are rarely seen, but often with poor outcome. In this case report we describe a lung transplant recipient with cystic fibrosis who developed a spondylodiscitis that was caused by Scedosporium apiospermum. The patient was treated with anti-fungal treatment by voriconazole for over three years with a clinical good response and without the need for surgical intervention. To our opinion this is the first anti-fungal treated case of invasive disease caused by Scedosporium/Pseudallescheria in a cystic fibrosis (CF) patient who underwent lung transplantation that survived.

Published
2011
Full Text
View/download PDF

34. Efficacy of sirolimus therapy for chylous effusions in lymphangioleiomyomatosis

Author

Barrera, P., Simons, S.O., Luijk, B., Wessels, M.J., and Heijdra, Y.F.

Subjects
Pathogenesis and modulation of inflammation [N4i 1], Evaluation of complex medical interventions Auto-immunity, transplantation and immunotherapy [NCEBP 2]
Abstract

Contains fulltext : 144856.pdf (Publisher’s version ) (Closed access)

Published
2013

36. A Multicenter Study on Long‐Term Outcomes After Lung Transplantation Comparing Donation After Circulatory Death and Donation After Brain Death

Author

Suylen, V., Luijk, B., Hoek, R. A. S., Graaf, E. A., Verschuuren, E. A., Van De Wauwer, C., Bekkers, J. A., Meijer, R. C. A., Bij, W., and Erasmus, M. E.

Abstract

The implementation of donation after circulatory death category 3 (DCD3) was one of the attempts to reduce the gap between supply and demand of donor lungs. In the Netherlands, the total number of potential lung donors was greatly increased by the availability of DCD3 lungs in addition to the initial standard use of donation after brain death (DBD) lungs. From the three lung transplant centers in the Netherlands, 130 DCD3 recipients were one‐to‐one nearest neighbor propensity score matched with 130 DBDrecipients. The primary end points were primary graft dysfunction (PGD), posttransplant lung function, freedom from chronic lung allograft dysfunction (CLAD), and overall survival. PGDdid not differ between the groups. Posttransplant lung function was comparable after bilateral lung transplantation, but seemed worse after DCD3 single lung transplantation. The incidence of CLAD(p = 0.17) nor the freedom from CLAD(p = 0.36) nor the overall survival (p = 0.40) were significantly different between both groups. The presented multicenter results are derived from a national context where one third of the lung transplantations are performed with DCD3 lungs. We conclude that the long‐term outcome after lung transplantation with DCD3 donors is similar to that of DBDdonors and that DCD3 donation can substantially enlarge the donor pool. This multicenter study demonstrates that lung transplantation using donation after circulatory death category 3 donors yields excellent short‐ and long‐term outcomes similar to donation after brain death. Bozso and Nagendran's editorial is on page 2507.

Published
2017
Full Text
View/download PDF

39. Reply

Author

van den Berge, M., primary, Luijk, B., additional, Bareille, P., additional, Dallow, N., additional, Postma, D. S., additional, and Lammers, J-W. J., additional

Published
2011
Full Text
View/download PDF

47. Effect of an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response.

Author

Luijk, B., van den Berge, M., Kerstjens, H. A. M., Postma, D. S., Cass, L., Sabin, A., and Lammers, J.-W. J.

Subjects
*ADENOSINES, *ALLERGENS, *ASTHMA, *LUNG diseases, *RESPIRATORY allergy, *BRONCHIAL diseases, *INTERLEUKIN-8
Abstract

Background: Adenosine receptor activation is suggested to play a role in asthmatic airway inflammation. Inhibition of adenosine receptors may have an effect on the late asthmatic response (LAR) after allergen inhalation and this mechanism could offer a potential new treatment in asthma. Methods: We evaluated the effect of an inhaled adenosine-2A (A2A)-receptor agonist (GW328267X), 25 μg, in 15 nonsmoking atopic asthmatics who underwent an inhaled allergen challenge following twice daily treatment for 1 week in a double-blind, placebo- and fluticasone propionate (250 μg) controlled study. Results: In contrast to fluticasone, treatment with the A2A-receptor agonist neither significantly protect against the allergen-induced early and late asthmatic reaction, nor the accompanying inflammatory response as measured by sputum total cell counts, number of EG2+ cells, and the concentration of interleukin-8 and eosinophil cationic protein. Conclusion: The inhaled A2A-receptor agonist, GW328267X, 25 μg does not affect the allergen-induced LAR or the associated inflammatory response in asthma. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

49. (297) - A Multicenter Study on Long-Term Outcomes after Lung Transplantation Comparing Donation after Circulatory Death and Donation after Brain Death.

Author

van Suylen, V., Luijk, B., Hoek, R.A., van de Graaf, E.A., Verschuuren, E.A., Van De Wauwer, C., Bekkers, J.A., Meijer, R.C., van der Bij, W., and Erasmus, M.E.

Subjects
*LUNG transplantation, *LONG-term care facilities, *BRAIN death, *MEDICAL research, *MEDICAL publishing, *COMPARATIVE studies
Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results